Detalhe da pesquisa
1.
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Oncologist
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417095
2.
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Future Oncol
; 19(20): 1397-1414, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318757
3.
Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
Oncologist
; 27(11): 907-918, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35925602
4.
Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting.
JCO Oncol Pract
; 20(3): 370-377, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194619
5.
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
Clin Lymphoma Myeloma Leuk
; 23(5): e222-e231, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925388
6.
Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.
Cancer Med
; 12(17): 17914-17923, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568276
7.
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.
Blood Cancer J
; 12(3): 46, 2022 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322025
8.
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
J Manag Care Spec Pharm
; 28(9): 980-988, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708343
9.
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pharmacoeconomics
; 40(8): 777-790, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696071
10.
Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
Leuk Lymphoma
; 59(1): 69-76, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28583027
11.
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
J Health Econ Outcomes Res
; 4(2): 188-203, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-37661948
12.
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
J Med Econ
; 20(10): 1056-1065, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28703659
13.
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
J Med Econ
; 20(1): 8-18, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27472034
14.
Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
J Clin Oncol
; 34(16): 1928-34, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27069082
15.
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Clin Lymphoma Myeloma Leuk
; 16(11): 625-636.e3, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686689
16.
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Clin Lymphoma Myeloma Leuk
; 14(5): 380-8, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25023616
17.
Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.
Leuk Lymphoma
; 58(8): 1968-1972, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28092998